China is set to incorporate commercial health insurance into its healthcare policy to address the increasing strain on public insurance caused by an ageing population and soaring medical costs. The annual surplus of the basic medical insurance fund has dwindled, falling to 470 billion yuan in 2024 for the second consecutive year, raising concerns about the sustainability of public financing for healthcare. Experts warn that the current system cannot cope with the growing demands for more comprehensive coverage, particularly as individuals in middle and high-income brackets begin to seek more advanced treatments not covered under basic plans.

While more than 95 percent of the Chinese population is covered by mandatory basic medical insurance, this leaves a significant gap for those seeking higher quality care. The introduction of commercial health insurance aims to bridge this gap while also fostering drug innovation. As the demand for medical services grows, the government recognizes that it can no longer adequately support the healthcare needs through its basic public insurance alone, which has seen a decrease in its surplus. The shift towards a dual system of public and commercial insurance represents a significant policy change in China's approach to healthcare financing.

This change comes amid ongoing pressures on the healthcare system due to an ageing demographic and the rising costs associated with medical treatments. The move to encourage commercial health insurance is intended not only to relieve financial pressures on the state but also to stimulate the pharmaceutical industry, potentially leading to improvements in drug availability and innovation. This strategy reflects a broader trend within China to enhance healthcare access and quality, ensuring that all citizens can receive the medical attention they need without overburdening public resources.